Rictor/mTORC2 Drives Progression and Therapeutic Resistance of HER2-Amplified Breast Cancers

Cancer Research - United States
doi 10.1158/0008-5472.can-15-3393
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Association for Cancer Research (AACR)

Related search

Her2 Cross Talk and Therapeutic Resistance in Breast Cancer

Frontiers in Bioscience - Landmark
ImmunologyMolecular BiologyBiochemistryMicrobiology MedicineGenetics
2008English

Breast Carcinoma With Amplified HER2: A Gene Expression Signature Specific for Trastuzumab Resistance and Poor Prognosis

Modern Pathology
Forensic MedicinePathology
2010English

Mechanisms Behind the Resistance to Trastuzumab in HER2-Amplified Breast Cancer and Strategies to Overcome It

Clinical Medicine Insights: Oncology
Oncology
2016English

Mechanisms of Resistance to Trastuzumab and Novel Therapeutic Strategies in HER2-Positive Breast Cancer

International Journal of Breast Cancer
Cancer ResearchOncologyPharmacology
2012English

MYC Is Amplified in BRCA1-Associated Breast Cancers

Clinical Cancer Research
Cancer ResearchOncology
2004English

Cancer Stem Cell Plasticity Drives Therapeutic Resistance

Cancers
Cancer ResearchOncology
2016English

A Phenotypic and Mechanistic Perspective on Heterogeneity of HER2-positive Breast Cancers

Molecular and Cellular Oncology
Cancer ResearchMolecular Medicine
2016English

Ibrutinib Inhibits ERBB Receptor Tyrosine Kinases and HER2-Amplified Breast Cancer Cell Growth

Molecular Cancer Therapeutics
Cancer ResearchOncology
2016English

Identification of New miRNA Biomarkers Associated With HER2-positive Breast Cancers

Oncoscience
Cancer ResearchOncology
2015English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy